Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Civica Rx
|
| gptkbp:age |
12 years and older
|
| gptkbp:CEO |
gptkb:Stéphane_Bancel
|
| gptkbp:clinicalTrials |
Phase 3
pediatric trials COVID-19_vaccine_trials |
| gptkbp:collaborations |
gptkb:Bill_&_Melinda_Gates_Foundation
|
| gptkbp:diseaseResistance |
94.1% (COVID-19)
|
| gptkbp:dosageForm |
two doses
|
| gptkbp:employees |
over 1,800
|
| gptkbp:founded |
2010
|
| gptkbp:founder |
Noubar Afeyan
|
| gptkbp:geographicalFeature |
over 70 countries
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Moderna, Inc.
|
| gptkbp:impact |
gptkb:Spikevax
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:is_part_of |
Operation Warp Speed
|
| gptkbp:notable_player |
gptkb:messenger_RNA_(mRNA)
mRNA vaccine federal government fatigue headache muscle pain nausea fever joint pain chills lipid nanoparticles lymphadenopathy rapid development process redness at injection site swelling at injection site -20°C for 6 months 2-8°C for 30 days for ages 12 to 17 for ages 18 and older for ages 5 to 11 for ages 6 months to 5 years for ages 6 to 11 full_approval_by_FDA |
| gptkbp:notableEvent |
mRNA-1273
|
| gptkbp:partnerships |
gptkb:Lonza_Group
gptkb:National_Institutes_of_Health |
| gptkbp:regulatoryCompliance |
Emergency_Use_Authorization_(EUA)
|
| gptkbp:research |
Tal Zaks
|
| gptkbp:research_focus |
infectious diseases
|
| gptkbp:revenue |
$18.5 billion (2021)
|
| gptkbp:safety |
monitored_by_CDC
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:stockExchange |
MRNA
|
| gptkbp:technology |
mRNA technology
|
| gptkbp:triggerType |
available
recommended for certain populations third dose |